James E. Dentzer - 04 Aug 2025 Form 4 Insider Report for Imunon, Inc. (IMNN)

Role
Director
Signature
/s/ Susan Eylward, Attorney-in-Fact for James E. Dentzer
Issuer symbol
IMNN
Transactions as of
04 Aug 2025
Net transactions value
+$30,526
Form type
4
Filing time
06 Aug 2025, 16:37:44 UTC
Previous filing
22 May 2025
Next filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dentzer James E Director C/O IMUNON, INC., 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE /s/ Susan Eylward, Attorney-in-Fact for James E. Dentzer 06 Aug 2025 0001400977

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMNN Common Stock Award $30,526 +3,318 $9.20 3,318 04 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMNN Stock Option (Right to Buy) Award $0 +250 $0.000000 250 04 Aug 2025 Common Stock 250 $9.20 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock granted in lieu of cash for portion of board fees
F2 Represents the closing price of Imunon, Inc. Common Stock on the date of grant.
F3 The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

Remarks:

On July 25, 2025, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-15 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person.